The effectiveness of therapeutic radionuclides (Lutetium-177) for prostate cancer treatment in Germany

According to statistics obtained during the international VISION and LuPSMA trials, the use of Lutetium-177 leads to a significant improvement in the results of laboratory tests and PET-CT (more than 57% of patients) and also improves quality (more than 70% of patients) and expectancy of life (more than 45% of patients).

At the moment, the only country where PSMA therapy with Lutetium-177 is certified and used with the highest efficiency, is Germany. Scientists from the German Cancer Research Center and the? University Hospital Heidelberg, were the first to create a carrier molecule PSMA-617. This is based on the same properties of which radioisotope therapy with Lutetium-177 is. Thanks to this carrier molecule, Germany has accumulated a unique evidence base and also practical experience regarding the application of this technique.?

More than 500 courses of radionuclide treatment for metastatic prostate cancer are carried out in the country annually. In Israel, Turkey and other countries, PSMA therapy with Lutetium-177 is a novel therapeutic option. No more than 100 patients receive such treatment annually. In addition, there is a lack of qualified doctors and the necessary technical bases in these countries. Due to this, the quality of the procedure and its effectiveness are limited.

Peptide receptor radionuclide therapy is carried out at specialized medical facilities which comply with strict radiation protection protocols and have access to the production of drugs for treatment using Lutetium-177 PSMA. In addition to? the selection of a clinic, it is important for the patients to find a competent doctor who will select the necessary dosage of the drug and the duration of the therapy course and will also carry out regular follow-up examinations.

In the absence of experience in treatment abroad, it is more convenient for the patients and their families to utilize the help of the Booking Health company. Booking Health is a medical tourism operator which has been organizing the treatment of men with prostate cancer abroad for more than 10 years.?

?? To find out more about the possibility of organising treatment abroad with our help, leave an application form at: https://bit.ly/3HlssY5

Our patient, John Baker, shares his experience of successfully undergoing Lutetium-177 PSMA therapy for prostate cancer:

#BookingHealth #treatment #doctor #Lutetium177 #Prostate #Prostatecancer #patient #treatmentabroad #therapy #treatmentngermany #medicalourism #medtourism #MensHealthAwareness #EarlyDetection #InnovationInHealthcare